Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells

Maurizio Fanciulli, Alessandra Valentini, Tiziana Bruno, Gennaro Citro, Gabriella Zupi, Aristide Floridi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The effect of lonidamine on glucose metabolism, hexokinase activity and adenylate pool of MCF-7 human breast cancer cells sensitive and resistant to adriamycin has been investigated. The following summarizes the results: 1. In both cell types the greatest part of glucose was metabolized to lactate, whereas only a small proportion of glucose carbon atoms was incorporated into CO2, lipids, nucleic acids, and supporting structures. 2. Glucose utilization, lactate production, and ATP content were higher in resistant cells due to a greater activity of mitochondrial hexokinase. 3. Lonidamine decreased glucose utilization, aerobic glycolysis and ATP content in both cell types and the effect was significantly higher on resistant cells. 4. The extent of inhibition in sensitive and resistant cells overlapped that found for mitochondrially bound hexokinase, thus indicating that the greater sensitivity of resistant cells to lonidamine was due to their higher amount of bound hexokinase. These findings confirmed a modified glucose metabolism in cells with resistant phenotype and suggested that lonidamine might be usefully used to reduce or overcome multidrug resistance of those cells with a reduced ability to accumulate and retain antitumor drugs.

Original languageEnglish
Pages (from-to)111-120
Number of pages10
JournalOncology Research
Volume8
Issue number3
Publication statusPublished - 1996

Fingerprint

Antineoplastic Agents
Doxorubicin
Breast Neoplasms
Glucose
Hexokinase
Lactic Acid
Adenosine Triphosphate
lonidamine
Multiple Drug Resistance
Glycolysis
Nucleic Acids
Carbon
Phenotype
Lipids

Keywords

  • glucose metabolism
  • lonidamine
  • MCF-7 cells
  • mitochondrial hexokinase
  • multidrug resistance

ASJC Scopus subject areas

  • Cancer Research

Cite this

Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells. / Fanciulli, Maurizio; Valentini, Alessandra; Bruno, Tiziana; Citro, Gennaro; Zupi, Gabriella; Floridi, Aristide.

In: Oncology Research, Vol. 8, No. 3, 1996, p. 111-120.

Research output: Contribution to journalArticle

Fanciulli, Maurizio ; Valentini, Alessandra ; Bruno, Tiziana ; Citro, Gennaro ; Zupi, Gabriella ; Floridi, Aristide. / Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells. In: Oncology Research. 1996 ; Vol. 8, No. 3. pp. 111-120.
@article{a0e9bad3bd894ca085e87270473e5694,
title = "Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells",
abstract = "The effect of lonidamine on glucose metabolism, hexokinase activity and adenylate pool of MCF-7 human breast cancer cells sensitive and resistant to adriamycin has been investigated. The following summarizes the results: 1. In both cell types the greatest part of glucose was metabolized to lactate, whereas only a small proportion of glucose carbon atoms was incorporated into CO2, lipids, nucleic acids, and supporting structures. 2. Glucose utilization, lactate production, and ATP content were higher in resistant cells due to a greater activity of mitochondrial hexokinase. 3. Lonidamine decreased glucose utilization, aerobic glycolysis and ATP content in both cell types and the effect was significantly higher on resistant cells. 4. The extent of inhibition in sensitive and resistant cells overlapped that found for mitochondrially bound hexokinase, thus indicating that the greater sensitivity of resistant cells to lonidamine was due to their higher amount of bound hexokinase. These findings confirmed a modified glucose metabolism in cells with resistant phenotype and suggested that lonidamine might be usefully used to reduce or overcome multidrug resistance of those cells with a reduced ability to accumulate and retain antitumor drugs.",
keywords = "glucose metabolism, lonidamine, MCF-7 cells, mitochondrial hexokinase, multidrug resistance",
author = "Maurizio Fanciulli and Alessandra Valentini and Tiziana Bruno and Gennaro Citro and Gabriella Zupi and Aristide Floridi",
year = "1996",
language = "English",
volume = "8",
pages = "111--120",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "3",

}

TY - JOUR

T1 - Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells

AU - Fanciulli, Maurizio

AU - Valentini, Alessandra

AU - Bruno, Tiziana

AU - Citro, Gennaro

AU - Zupi, Gabriella

AU - Floridi, Aristide

PY - 1996

Y1 - 1996

N2 - The effect of lonidamine on glucose metabolism, hexokinase activity and adenylate pool of MCF-7 human breast cancer cells sensitive and resistant to adriamycin has been investigated. The following summarizes the results: 1. In both cell types the greatest part of glucose was metabolized to lactate, whereas only a small proportion of glucose carbon atoms was incorporated into CO2, lipids, nucleic acids, and supporting structures. 2. Glucose utilization, lactate production, and ATP content were higher in resistant cells due to a greater activity of mitochondrial hexokinase. 3. Lonidamine decreased glucose utilization, aerobic glycolysis and ATP content in both cell types and the effect was significantly higher on resistant cells. 4. The extent of inhibition in sensitive and resistant cells overlapped that found for mitochondrially bound hexokinase, thus indicating that the greater sensitivity of resistant cells to lonidamine was due to their higher amount of bound hexokinase. These findings confirmed a modified glucose metabolism in cells with resistant phenotype and suggested that lonidamine might be usefully used to reduce or overcome multidrug resistance of those cells with a reduced ability to accumulate and retain antitumor drugs.

AB - The effect of lonidamine on glucose metabolism, hexokinase activity and adenylate pool of MCF-7 human breast cancer cells sensitive and resistant to adriamycin has been investigated. The following summarizes the results: 1. In both cell types the greatest part of glucose was metabolized to lactate, whereas only a small proportion of glucose carbon atoms was incorporated into CO2, lipids, nucleic acids, and supporting structures. 2. Glucose utilization, lactate production, and ATP content were higher in resistant cells due to a greater activity of mitochondrial hexokinase. 3. Lonidamine decreased glucose utilization, aerobic glycolysis and ATP content in both cell types and the effect was significantly higher on resistant cells. 4. The extent of inhibition in sensitive and resistant cells overlapped that found for mitochondrially bound hexokinase, thus indicating that the greater sensitivity of resistant cells to lonidamine was due to their higher amount of bound hexokinase. These findings confirmed a modified glucose metabolism in cells with resistant phenotype and suggested that lonidamine might be usefully used to reduce or overcome multidrug resistance of those cells with a reduced ability to accumulate and retain antitumor drugs.

KW - glucose metabolism

KW - lonidamine

KW - MCF-7 cells

KW - mitochondrial hexokinase

KW - multidrug resistance

UR - http://www.scopus.com/inward/record.url?scp=0029952517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029952517&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 111

EP - 120

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 3

ER -